

Meeting abstract

Open Access

Benzodiazepines modulate GABA_A receptors by reducing a gamma-subunit-mediated inhibition of GABA sensitivity

Igor Baburin¹, Sophia Khom¹, Eugen Timin¹, Annette Hohaus¹, Werner Sieghart² and Steffen Hering*¹

Address: ¹Department of Pharmacology and Toxicology, University of Vienna, 1090 Vienna, Austria and ²Department of Biochemistry and Molecular Biology, Center for Brain Research, Medical University of Vienna, 1090 Vienna, Austria

Email: Steffen Hering* - steffen.hering@univie.ac.at

* Corresponding author

from 15th Scientific Symposium of the Austrian Pharmacological Society (APHAR) Joint meeting with the Hungarian Society of Experimental and Clinical Pharmacology (MFT) and the Slovenian Pharmacological Society (SDF) Graz, Austria. 19-21 November 2009

Published: 12 November 2009

BMC Pharmacology 2009, 9(Suppl 2):A23 doi:10.1186/1471-2210-9-S2-A23

This abstract is available from: <http://www.biomedcentral.com/1471-2210/9/S2/A23>

© 2009 Baburin et al; licensee BioMed Central Ltd.

Background

Heterologous expression of α_1 , β_2 and $\gamma_{2S}(\gamma_1)$ subunits produces a mixed population of GABA_A receptors containing $\alpha_1\beta_2$ or $\alpha_1\beta_2\gamma_{2S}(\gamma_1)$ subunits. GABA sensitivity (lower in receptors containing γ_1 or γ_{2S} subunits) and the potentiation of GABA-activated chloride currents (I_{GABA}) by benzodiazepines (BZDs) are dependent on $\gamma_{2S}(\gamma_1)$ incorporation [1]. A variable γ subunit incorporation may affect the estimation of I_{GABA} potentiation by BZDs. We propose an approach for estimation of BZD efficiency that accounts for a mixed population of $\alpha_1\beta_2$ and $\alpha_1\beta_2\gamma_{2S}(\gamma_1)$ receptors.

Methods

We investigated the relation between GABA sensitivity (EC_{50}) and BZD modulation by analyzing triazolam-, clonazepam- and midazolam-induced potentiation of I_{GABA} in *Xenopus* oocytes under two-microelectrode voltage clamp.

Results

Plotting EC_{50} versus BZD-induced shifts of GABA concentration-response curves ($\Delta EC_{50}(\text{BZD})$) of oocytes injected with different amounts of α_1 , β_2 and $\gamma_{2S}(\gamma_1)$ cRNA (1:1:1-1:1:10) revealed a linear regression between $\gamma_{2S}(\gamma_1)$ -mediated reduction of GABA sensitivity (EC_{50}) and $\Delta EC_{50}(\text{BZD})$. The slope factors of the regression were

always higher for oocytes expressing $\alpha_1\beta_2\gamma_1$ subunit receptors (triazolam: 1.8 ± 0.1 ; clonazepam: 1.6 ± 0.1 ; midazolam: 2.3 ± 0.2) than for oocytes expressing $\alpha_1\beta_2\gamma_{2S}$ receptors (triazolam: 1.4 ± 0.1 ; clonazepam: 1.4 ± 0.1 ; midazolam: 1.3 ± 0.1). Mutant GABA_A receptors ($\alpha_1\beta_2\text{-R207C}\gamma_{2S}$) with lower GABA sensitivity showed higher drug efficiencies (slope factors: triazolam: 1.1 ± 0.1 ; clonazepam: 1.1 ± 0.1 ; midazolam: 1.2 ± 0.1) whereas higher GABA sensitivity of $\alpha_1\text{-L263S}\beta_2\gamma_{2S}$ mutant receptors was associated with lower efficiency (slope factor: clonazepam: 1.7 ± 0.1).

Conclusion

Regression analysis enabled the estimation of BZD efficiency when variable mixtures of $\alpha_1\beta_2$ and $\alpha_1\beta_2\gamma_{2S}(\gamma_1)$ receptors are expressed and provided new insights into the $\gamma_{2S}(\gamma_1)$ dependency of BZD action. The method for determining the slope of the regression line also allowed the determination of the percentage of $\alpha_1\beta_2\gamma_{2S}$ receptors. Assuming a twofold difference in the single channel conductance of $\alpha_1\beta_2$ and $\alpha_1\beta_2\gamma_{2S}$ receptors, at 70% current ratio of γ_{2S} -containing receptors our mathematical model predicts only about 50% of γ_{2S} subunit incorporation. Our data suggest that BZDs reduce a γ -subunit-mediated inhibition of GABA sensitivity.

Acknowledgements

This work was supported by FWF grant I5914 (SH).

References

1. Boileau AJ, Baur R, Sharkey LM, Sigel E, Czajkowski C: **The relative amount of cRNA coding for $\gamma 2$ subunits affects stimulation by benzodiazepines in GABA_A receptors expressed in *Xenopus* oocytes.** *Neuropharmacology* 2002, **43**:695-700.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

